Drug Type Small molecule drug |
Synonyms TAK 901 |
Target |
Action inhibitors |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H32N4O3S |
InChIKeyWKDACQVEJIVHMZ-UHFFFAOYSA-N |
CAS Registry934541-31-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Oct 2009 | |
Acute Lymphoblastic Leukemia | Phase 1 | United States | 01 Mar 2009 | |
Acute Myeloid Leukemia | Phase 1 | United States | 01 Mar 2009 | |
Chronic Lymphocytic Leukemia | Phase 1 | United States | 01 Mar 2009 | |
Multiple Myeloma | Phase 1 | United States | 01 Mar 2009 | |
Myelodysplastic Syndromes | Phase 1 | United States | 01 Mar 2009 | |
Myelofibrosis | Phase 1 | United States | 01 Mar 2009 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | United States | 01 Mar 2009 | |
Polycythemia | Phase 1 | United States | 01 Mar 2009 | |
Primary Myelofibrosis | Phase 1 | United States | 01 Mar 2009 |